Cargando…

Bowen’s disease – a review of newer treatment options

Bowen’s disease (squamous cell carcinoma in situ) has a 3%–5% risk to develop into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer among Caucasians and its incidence has increased during the last decades dramatically. Multiple treatment options for Bowen’s diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Neubert, Thorsten, Lehmann, Percy
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621408/
https://www.ncbi.nlm.nih.gov/pubmed/19209288
_version_ 1782163409374019584
author Neubert, Thorsten
Lehmann, Percy
author_facet Neubert, Thorsten
Lehmann, Percy
author_sort Neubert, Thorsten
collection PubMed
description Bowen’s disease (squamous cell carcinoma in situ) has a 3%–5% risk to develop into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer among Caucasians and its incidence has increased during the last decades dramatically. Multiple treatment options for Bowen’s disease have been described and are established with advantages and disadvantages. Bowen’s disease occurs more often in elderly patients (with a higher risk of comorbidities) and is frequently located on body sites with poor wound healing. Therefore there is need for non-invasive/non-destructive but effective treatment options. We would like to give an overview of established therapies and more detailed information about the newer treatment options for Bowen’s disease with topical diclofenac, topical imiquimod and photodynamic therapy.
format Text
id pubmed-2621408
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26214082009-02-10 Bowen’s disease – a review of newer treatment options Neubert, Thorsten Lehmann, Percy Ther Clin Risk Manag Review Bowen’s disease (squamous cell carcinoma in situ) has a 3%–5% risk to develop into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer among Caucasians and its incidence has increased during the last decades dramatically. Multiple treatment options for Bowen’s disease have been described and are established with advantages and disadvantages. Bowen’s disease occurs more often in elderly patients (with a higher risk of comorbidities) and is frequently located on body sites with poor wound healing. Therefore there is need for non-invasive/non-destructive but effective treatment options. We would like to give an overview of established therapies and more detailed information about the newer treatment options for Bowen’s disease with topical diclofenac, topical imiquimod and photodynamic therapy. Dove Medical Press 2008-10 2008-10 /pmc/articles/PMC2621408/ /pubmed/19209288 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Neubert, Thorsten
Lehmann, Percy
Bowen’s disease – a review of newer treatment options
title Bowen’s disease – a review of newer treatment options
title_full Bowen’s disease – a review of newer treatment options
title_fullStr Bowen’s disease – a review of newer treatment options
title_full_unstemmed Bowen’s disease – a review of newer treatment options
title_short Bowen’s disease – a review of newer treatment options
title_sort bowen’s disease – a review of newer treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621408/
https://www.ncbi.nlm.nih.gov/pubmed/19209288
work_keys_str_mv AT neubertthorsten bowensdiseaseareviewofnewertreatmentoptions
AT lehmannpercy bowensdiseaseareviewofnewertreatmentoptions